I
Ivan Stamenkovic
Researcher at University Hospital of Lausanne
Publications - 56
Citations - 10480
Ivan Stamenkovic is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Regulation of gene expression & Stromal cell. The author has an hindex of 34, co-authored 56 publications receiving 8677 citations. Previous affiliations of Ivan Stamenkovic include Icahn School of Medicine at Mount Sinai & University of Lausanne.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Cyril Neftel,Julie Laffy,Mariella G. Filbin,Toshiro Hara,Marni E. Shore,Marni E. Shore,Gilbert J. Rahme,Gilbert J. Rahme,Alyssa R. Richman,Alyssa R. Richman,Dana Silverbush,Dana Silverbush,McKenzie Shaw,Christine M. Hebert,Christine M. Hebert,John M. DeWitt,John M. DeWitt,Simon Gritsch,Simon Gritsch,Elizabeth M. Perez,Elizabeth M. Perez,L. Nicolas Gonzalez Castro,Xiaoyang Lan,Xiaoyang Lan,Nicholas Druck,Christopher Rodman,Danielle Dionne,Alexander Kaplan,Mia Bertalan,Julia L. Small,Kristine Pelton,Sarah Becker,Dennis M. Bonal,Quang-Dé Nguyen,Rachel L. Servis,Jeremy M. Fung,Ravindra Mylvaganam,Lisa Mayr,Johannes Gojo,Christine Haberler,René Geyeregger,Thomas Czech,Irene Slavc,Brian V. Nahed,William T. Curry,Bob S. Carter,Hiroaki Wakimoto,Priscilla K. Brastianos,Tracy T. Batchelor,Anat Stemmer-Rachamimov,Maria Martinez-Lage,Matthew P. Frosch,Ivan Stamenkovic,Nicolo Riggi,Esther Rheinbay,Esther Rheinbay,Michelle Monje,Orit Rozenblatt-Rosen,Daniel P. Cahill,Anoop P. Patel,Tony Hunter,Inder M. Verma,Keith L. Ligon,Keith L. Ligon,David N. Louis,Aviv Regev,Aviv Regev,Bradley E. Bernstein,Bradley E. Bernstein,Itay Tirosh,Mario L. Suvà,Mario L. Suvà +71 more
TL;DR: It is found that malignant cells in glioblastoma exist in four main cellular states that recapitulate distinct neural cell types, are influenced by the tumor microenvironment, and exhibit plasticity.
Journal ArticleDOI
Extracellular matrix remodelling: the role of matrix metalloproteinases.
TL;DR: MMPs play an important role in the control of cellular interactions with and response to their environment in conditions that promote tissue turnover, be they physiological or pathological, such as inflammation and cancer.
Journal ArticleDOI
Functional structure and composition of the extracellular matrix.
Fred T. Bosman,Ivan Stamenkovic +1 more
TL;DR: The extracellular matrix appears to be a very dynamic structure, which has a prominent role in normal development as well as in a variety of disease processes and Matrix metalloproteinases are essential actors in this complex interplay between cells and the extrace cellular matrix.
Journal Article
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
TL;DR: This work addressed the involvement of the FasL/Fas signaling pathway in doxorubicin-induced apoptosis and the ability of matrix metalloproteinases (MMPs) to proteolytically cleave FasL in tumor cells.